ProCE Banner Activity

An Interactive Tool for Managing AEs With CDK4/6 Inhibitors for HR+, HER2– Breast Cancer

Tool

Use this interactive tool to learn strategies to assess and manage adverse events associated with CDK4/6 inhibitor therapy for HR-positive/HER2-negative breast cancer.

Released: April 11, 2025

Expiration: April 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP

Breast Oncology Nurse Practitioner
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP: consultant/advisor/speaker: Hologic, Stemline Therapeutics.

Laura Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: AstraZeneca, Genentech, Gilead, Lilly, Merck; other (travel support): Lilly.